Skip to main content

Table 2 The association between quintile of cumulative average serum urate and all-cause and cause-specific mortality

From: Repeated measurements of serum urate and mortality: a prospective cohort study of 152,358 individuals over 8 years of follow-up

 

Q1

Q2

Q3

Q4

Q5

All-cause mortality

 Population no. (cases)

30,475 (1713)

30,526 (1507)

30,455 (1462)

30,461 (1373)

30,441 (1509)

 Incidence rate, per 1000 person-years

7.41

6.45

6.38

6.15

7.17

 Age- and sex-adjusted HR

1.19 (1.11–1.27)

0.99 (0.92–1.06)

1 (ref)

0.97 (0.90–1.05)

1.11 (1.03–1.19)

 Multiple adjusted HR*

1.12 (1.04–1.20)

0.97 (0.90–1.04)

1 (ref)

0.98 (0.91–1.05)

1.07 (0.99–1.15)

 In 121,110 men HR*

1.11 (1.03–1.20)

0.97 (0.90–1.05)

1 (ref)

0.98 (0.91–1.06)

1.07 (0.99–1.16)

 In 30,081 women HR*

1.35 (1.03–1.77)

0.98 (0.74–1.30)

1 (ref)

0.92 (0.70–1.21)

0.99 (0.77–1.29)

Cardiovascular mortality

 Population no. (cases)

30,475 (354)

30,526 (334)

30,455 (323)

30,461 (352)

30,441 (400)

 Incidence rate, per 1000 person-years

1.53

1.43

1.41

1.57

1.89

 Multiple adjusted HR*

1.06 (0.91–1.23)

0.98 (0.84–1.14)

1 (ref)

1.11 (0.96–1.30)

1.20 (1.03–1.40)

 In 121,110 men HR*

1.04 (0.89–1.22)

0.97 (0.83–1.14)

1 (ref)

1.11 (0.95–1.30)

1.20 (1.02–1.40)

 In 30,081 women HR*

1.55 (0.83–2.89)

1.08 (0.57–2.06)

1 (ref)

1.20 (0.66–2.17)

1.39 (0.80–2.42)

Cancer mortality

 Population no. (cases)

30,475 (397)

30,526 (351)

30,455 (386)

30,461 (314)

30,441 (258)

 Incidence rate, per 1000 person-years

1.71

1.50

1.68

1.40

1.22

 Multiple adjusted HR*

1.00 (0.87–1.16)

0.87 (0.75–1.00)

1 (ref)

0.85 (0.73–0.99)

0.73 (0.62–0.86)

 In 121,110 men HR*

0.98 (0.85–1.14)

0.85 (0.73–0.99)

1 (ref)

0.85 (0.73–0.99)

0.70 (0.59–0.83)

 In 30,081 women HR*

1.36 (0.81–2.30)

1.11 (0.65–1.88)

1 (ref)

0.92 (0.54–1.59)

0.99 (0.59–1.66)

Other mortalities

 Population no. (cases)

30,475 (367)

30,526 (328)

30,455 (285)

30,461 (267)

30,441 (325)

 Incidence rate, per 1000 person-years

1.58

1.40

1.24

1.19

1.54

 Multiple adjusted HR*

1.18 (1.01–1.38)

1.06 (0.91–1.25)

1 (ref)

1.00 (0.84–1.18)

1.22 (1.04–1.44)

 In 121,110 men HR*

1.18 (1.00–1.39)

1.07 (0.91–1.26)

1 (ref)

1.00 (0.84–1.19)

1.21 (1.02–1.44)

 In 30,081 women HR*

1.29 (0.72–2.34)

0.97 (0.52–1.79)

1 (ref)

0.90 (0.49–1.67)

1.19 (0.67–2.09)

  1. *Model adjusted for age (years); sex; baseline serum urate (mmol/L); smoke status (current, past, or never); alcohol consumption status (current, past, or never); physical activity (never, sometimes, or active); average monthly income of each family member (< 500, 500–2999, or ≥ 3000¥); education (illiteracy/elementary school, middle school, or college/university); sodium intake (< 6.0, 6.0–9.9, or ≥ 10.0 g/day); father and mother’s cardiovascular disease history (yes or no); use of aspirin, antihypertensive, hypoglycemic, and lipid-lowering agents (yes/no for each); systolic blood pressure (quintile); diastolic blood pressure (quintile); fasting blood glucose (< 4.0, 4.0–5.5, 5.6–6.9, or ≥ 7 mmol/L); triglycerides (< 1.7, 1.7–2.2, 2.3–5.5, or ≥ 5.6 mmol/L); low-density lipoprotein cholesterol (< 1.80, 1.80–3.33, 3.34–4.91, or ≥ 4.92 mmol/L); body mass index (< 25.0, 25.0–29.9, or ≥ 30 kg/m2); high sensitive C-reactive protein (< 1, 1–2.9, or ≥ 3 mg/L); and estimated glomerular filtration rate (< 30, 30–59, 60–89, or ≥ 90 mL/min/1.73 m2)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us